Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal meningitis
- Focus Pharmacodynamics
- Sponsors sanofi pasteur
- 29 Sep 2017 Planned End Date changed from 1 Apr 2018 to 15 Dec 2017.
- 27 Sep 2017 This trial has been completed in spain.
- 28 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 15 Dec 2017.